Management
Revolutionising the treatment of food allergy
Our global leadership team combines key immunology, drug development and management experience to drive the clinical development of our immunotherapies through to commercialisation.
Pascal Hickey
Chief Executive Officer
Pascal Hickey
Chief Executive Officer
Pascal Hickey has over 25 years’ international experience in drug development. He has held management responsibilities across various R&D functions in innovative and rapidly growing biotechnology companies, and has over 15 years' experience in allergy. Prior to joining Aravax, Pascal was Vice President Early Development at Circassia Pharmaceuticals (UK).
Pascal received his Bachelor of Pharmacy from the Victorian College of Pharmacy and PhD from Monash University, Australia.
Sara Prickett
Chief Scientific Officer
Sara Prickett
Chief Scientific Officer
Sara Prickett has over 20 years’ research experience in cellular immunology and was responsible for the preclinical development of Aravax's peanut allergy immunotherapy, PVX108. Prior to Aravax, Sara held senior research posts at Alfred Health and Monash University where she played a major role in the research underpinning the peanut allergy therapy being developed by Aravax. She is a co-inventor, and co-founder of the company.
Sara received her Bachelor of Science from Sheffield University and PhD from Imperial College, London.
Aled Williams
Chief Business Officer
Aled Williams
Chief Business Officer
Aled Williams has more than 25 years of leadership experience across pharma and biotech sectors. Aled's experience includes being Chief Executive Officer of Enthera Pharmaceuticals, Chief Business Officer at Polyneuron Pharmaceuticals and Chief Commercial Officer at both VectivBio and Therachon. Aled's prior experience includes more than seven years at Shire, where he was Vice President and Global Strategy Head and led three of the rare disease therapeutic areas, globally. Prior to Shire, he held leadership positions of increasing responsibility at Bristol-Myers Squibb, Novartis and Roche. Aled originally trained in microbiology and started his career working in Public Health.
Louise Peacock
Chief Regulatory and Quality Officer
Louise Peacock
Chief Regulatory and Quality Officer
Louise has over 35 years regulatory and development experience from working in both small and large pharmaceutical companies including Abbott Laboratories, Auxilium Pharmaceuticals, Intermune, Circassia, Aimmune and Alladapt Immunotherapeutics. Most recently, before joining Aravax, Louise was Chief Regulatory and Quality Officer at Vaderis Therapeutics AG.
Louise received her BSc (Hons) Pharmacology from Kings College, London and her LLB (Hons) from the University of West London.
Kevin Fischer
Chief Financial Officer
Kevin Fischer
Chief Financial Officer
Kevin is a seasoned finance professional with more than 20 years’ experience in strategic financial management, operational leadership, risk oversight, and corporate governance. He is a Fellow Member of CPA Australia (FCPA) and the Governance Institute of Australia (FGIA), and holds a Bachelor of Commerce degree from the University of Natal in South Africa.
Kevin has held senior finance roles across both private and public sectors, including prominent positions at Wavewise Analytics Pty Ltd, Gallagher eShepherd Pty Ltd, QIAGEN, Cellestis Limited, and Genetic Technologies Limited, partnering closely with boards and executive teams to deliver robust outcomes.
Paul Laidler
VP Product Development
Paul Laidler
VP Product Development
Paul has over 25 years' pharmaceutical development experience having held several roles within large Pharma companies including AstraZeneca and a number of rapidly developing biotechnology companies including PowderJect Technologies, Chiron Vaccines, PowderMed and most recently Circassia Pharmaceuticals. Prior to setting up as an independent consultant, Paul was Vice President of Pharmaceutical Sciences at Circassia Pharmaceuticals.
Paul received both his Bachelor of Pharmacy and PhD degrees from King’s College London.
Andrew Humberstone
Director Clinical Development
Andrew Humberstone
Director Clinical Development
Andrew has over 25 years regulatory and clinical development experience in both small and large pharmaceutical companies including SmithKline Beecham (UK), Allergan (France), Acrux (Australia), Shire (Switzerland). Most recently, before joining Aravax, he was Vice President Clinical Science at ObsEva in Geneva.
Andrew received his BSc (Hons) Pharm from the University of Manchester and PhD from Monash University.
Annette Leahy
Director Clinical Operations
Annette Leahy
Director Clinical Operations
Annette brings 20 years of clinical research experience in operational and project management roles across biotechnology, pharmaceutical, and contract research organisations.
Her project management experience spans managing Phase 1 and 2 studies through to leading large Phase 3 multinational clinical programs, in roles at Opthea, Biota, Nucleus Network and Mitsubishi Pharma (UK). She has also held senior leadership roles at Swisse Wellness and Novotech.
Annette holds a Bachelor of Health Information Management from La Trobe University.
